Our program utilizes a collaborative, multi-disciplinary team approach—we believe that is the best way to treat you as a whole person and address your health care needs in a comprehensive fashion. In addition to hematology and medical oncology physicians with vast experience in multiple myeloma and related diseases, the team includes skilled nurse practitioners, physician assistants, registered nurses, clinical social workers, dietitians, and pharmacists. The team also includes leading experts from Mount Sinai’s Bone Marrow Transplant Program and Cellular Therapy Service and specialists from other services such as Pathology, Radiology, Immunology, Genomics, Infectious Diseases, Orthopedic Surgery, Cardiology, and Nephrology.   As a patient at Mount Sinai, you have access to the finest doctors in all medical specialties.

Every patient is unique. Based on a thorough assessment of your disease, we will work with you to craft an individualized treatment plan that takes into account your medical history and condition, as well as your lifestyle and personal preferences. And, we will work closely with your referring physician to ensure continuity of your care.

We welcome patients from the local region and across the United States, as well as international patients. We are committed to meeting the individual needs of each patient in an environment of compassion, comfort, and excellence.

Our program is led by Sundar Jagannath, MD, a highly regarded expert with more than 30 years of experience. In 1989, he helped establish the first program ever entirely dedicated to myeloma research and patient care at the University of Arkansas for Medical Sciences. Dr. Jagannath and his colleagues in Arkansas employed autologous stem cell transplantation with a novel clinical approach, achieving remarkable improvements in survival.

Since joining Mount Sinai in 2010 from the now-closed St. Vincent's Hospital-Manhattan, Dr. Jagannath has continued to advance clinical care and mentor a team of outstanding myeloma physicians, with the goal of improving patient outcomes.

We are an integral part of The Tisch Cancer Institute, which is a National Cancer Institute-Designated Cancer Center. This designation recognizes our standards of excellence and breakthrough accomplishments in research aimed at prevention and cure.

As an academic medical complex, the Mount Sinai Health System is affiliated with the Icahn School of Medicine. We are proud to participate in the education of the next generation of myeloma experts.